Acrivon Therapeutics, Inc. Common Stock (ACRV) vs Humacyte, Inc. (HUMA)

A side-by-side comparison of Acrivon Therapeutics, Inc. Common Stock and Humacyte, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare
Acrivon Therapeutics, Inc. Common Stock logo
ACRV
Acrivon Therapeutics, Inc. Common Stock
$81M
$1.89HealthcareDelayed quote: Oct 6, 2026, 2:44 PM EDT
Humacyte, Inc. logo
HUMA
Humacyte, Inc.
$82M
$0.49HealthcareDelayed quote: Oct 6, 2026, 2:45 PM EDT

Total return — ACRV vs HUMA

growth of $100 · dividends reinvested · last 4y
ACRV -88.1% (-41.3%/yr)HUMA -84.1% (-36.9%/yr)HUMA compounded faster over this window
0100200300Start $1002023202420252026$12$16
ACRV HUMA

ACRV vs HUMA: by the numbers

  • •HUMA is the larger company ($82M vs $81M market cap).
  • •Both run net losses; ACRV's is the smaller (0.00% vs -4560.82% net margin).

Metrics side by side

Valuation

MetricACRVHUMA
P/S ratioN/A38.84
P/B ratio0.932.64

Profitability

MetricACRVHUMA
Gross margin0.00%-736.46%
Operating margin0.00%-5271.69%
Net margin0.00%-4560.82%
ROE-85.65%-309.44%
ROIC-88.28%-90.27%

Growth (annualized)

MetricACRVHUMA
Revenue CAGR (5Y)N/A2.41%
Total return CAGR (5Y)N/A-45.73%

Go deeper

Full ACRV analysisFull HUMA analysisInteractive comparison tool

Dig into the metrics

Acrivon Therapeutics, Inc. Common Stock ROEHumacyte ROEAcrivon Therapeutics, Inc. Common Stock operating marginHumacyte operating marginAcrivon Therapeutics, Inc. Common Stock revenue growthHumacyte revenue growthAcrivon Therapeutics, Inc. Common Stock free cash flowHumacyte free cash flow

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.